CCCC C4 Therapeutics, Inc. Stock Quote

CCCC [NASD]

Index	-	P/E	-	EPS (ttm)	-2.19	Insider Own	0.50%	Shs Outstand	48.92M	Perf Week	-16.84%
Market Cap	467.36M	Forward P/E	-	EPS next Y	-2.94	Insider Trans	0.00%	Shs Float	43.45M	Perf Month	-16.14%
Income	-106.60M	PEG	-	EPS next Q	-0.74	Inst Own	82.30%	Short Float / Ratio	9.09% / 8.15	Perf Quarter	-21.72%
Sales	48.30M	P/S	9.68	EPS this Y	-18.30%	Inst Trans	-1.77%	Short Interest	3.95M	Perf Half Y	10.19%
Book/sh	6.50	P/B	1.23	EPS next Y	-14.40%	ROA	-21.60%	Target Price	23.31	Perf Year	-77.75%
Cash/sh	5.37	P/C	1.49	EPS next 5Y	-	ROE	-30.10%	52W Range	4.84 - 38.05	Perf YTD	-75.16%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-20.50%	52W High	-78.48%	Beta	-
Dividend %	-	Quick Ratio	7.20	Sales past 5Y	-	Gross Margin	-	52W Low	69.21%	ATR	0.82
Employees	121	Current Ratio	7.20	Sales Q/Q	-20.00%	Oper. Margin	-	RSI (14)	42.31	Volatility	13.77% 10.05%
Optionable	Yes	Debt/Eq	0.04	EPS Q/Q	-28.30%	Profit Margin	-	Rel Volume	0.64	Prev Close	8.00
Shortable	Yes	LT Debt/Eq	0.03	Earnings	-	Payout	-	Avg Volume	484.31K	Price	8.19
Recom	2.50	SMA20	-9.49%	SMA50	-7.19%	SMA200	-29.74%	Volume	36,751	Change	2.37%

Nov-04-22

Downgrade

JP Morgan

Overweight → Neutral

$22 → $15

Oct-11-22

Initiated

Morgan Stanley

Underweight

Apr-28-22

Initiated

Credit Suisse

Underperform

$10

Apr-11-22

Downgrade

BofA Securities

Buy → Neutral

$46 → $15

Mar-10-22

Initiated

JP Morgan

Overweight

$43

Feb-11-22

Resumed

BMO Capital Markets

Outperform

$57

Feb-10-22

Initiated

Wells Fargo

Equal Weight

$25

Nov-23-21

Initiated

BofA Securities

Buy

$54

Oct-14-21

Initiated

SVB Leerink

Mkt Perform

$20

Sep-30-21

Initiated

Stifel

Hold

$45

Show Previous Ratings

Nov-13-22 07:13AM	The past year for C4 Therapeutics (NASDAQ:CCCC) investors has not been profitable Simply Wall St.
Nov-08-22 09:55AM	Wall Street Analysts Think C4 Therapeutics, Inc. (CCCC) Could Surge 227%: Read This Before Placing a Bet Zacks
Nov-03-22 08:25AM	C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:00AM	C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights GlobeNewswire
Nov-02-22 10:01AM	C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks -5.27%
09:02AM	Loading…
Oct-03-22 09:02AM	One C4 Therapeutics, Inc. (NASDAQ:CCCC) insider upped their stake in the previous year Simply Wall St.
Sep-29-22 07:00AM	C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC Degrader, in BRAF-V600 Mutant Solid Cancers GlobeNewswire -5.01%
Sep-26-22 07:00AM	C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022 GlobeNewswire
Sep-06-22 08:22AM	With 63% ownership of the shares, C4 Therapeutics, Inc. (NASDAQ:CCCC) is heavily dominated by institutional owners Simply Wall St.
Aug-10-22 06:05AM	Growth Investors: Industry Analysts Just Upgraded Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Revenue Forecasts By 16% Simply Wall St.
Aug-07-22 08:21AM	Analysts Are Upgrading C4 Therapeutics, Inc. (NASDAQ:CCCC) After Its Latest Results Simply Wall St.
Aug-04-22 09:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates Zacks +6.95%
08:00AM	C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights GlobeNewswire
Aug-02-22 08:00AM	C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors GlobeNewswire +6.01%
May-16-22 08:00AM	C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors GlobeNewswire -6.15%
09:15AM	Loading…
May-05-22 09:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates Zacks
08:00AM	C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights GlobeNewswire
Apr-08-22 02:15PM	C4 Therapeutics Stock Falls On CFT7455 Dose Limiting Toxicity In Multiple Myeloma Trial Benzinga -50.57%
01:00PM	C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader GlobeNewswire
10:05AM	Investors one-year losses grow to 32% as the stock sheds US$66m this past week Simply Wall St.
Mar-17-22 11:44AM	J.P. Morgan Says Theres Room for Over 80% Gains in These 2 Stocks TipRanks +5.92%
Mar-16-22 04:05PM	C4 Therapeutics Appoints Utpal Koppikar to Board of Directors GlobeNewswire +5.30%
Mar-09-22 08:00AM	C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue Sarcoma GlobeNewswire +15.29%
Mar-08-22 04:30PM	C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022 GlobeNewswire
Feb-24-22 07:00AM	C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights GlobeNewswire +13.96%
Feb-07-22 04:45AM	What Is The Ownership Structure Like For C4 Therapeutics, Inc. (NASDAQ:CCCC)? Simply Wall St.
Jan-12-22 11:09AM	Is C4 Therapeutics, Inc. (CCCC) A Good Stock To Buy? Insider Monkey
Jan-10-22 07:00AM	C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio GlobeNewswire +8.52%
Jan-03-22 07:00AM	C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-29-21 12:00PM	What Makes C4 Therapeutics, Inc. (CCCC) a New Buy Stock Zacks
08:00AM	Loading…
Dec-17-21 08:00AM	C4 Therapeutics Added to NASDAQ Biotechnology Index GlobeNewswire
Dec-01-21 07:28AM	C4 Therapeutics (CCCC) Sees Hammer Chart Pattern: Time to Buy? Zacks -7.35%
Nov-22-21 12:00PM	C4 Therapeutics, Inc. (CCCC) Moves to Buy: Rationale Behind the Upgrade Zacks
Nov-10-21 04:01PM	C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results GlobeNewswire
08:34AM	Why C4 Therapeutics (CCCC) Might Surprise This Earnings Season Zacks
Oct-26-21 10:41AM	Hedge Funds Are Piling Into C4 Therapeutics, Inc. (CCCC) Insider Monkey
Oct-09-21 09:14AM	C4 Therapeutics (NASDAQ:CCCC) pulls back 8.2% this week, but still delivers shareholders notable 85% return over 1 year Simply Wall St.
Sep-17-21 10:27AM	Director Of C4 Therapeutics Sold $3.98 Million In Stock Benzinga
Aug-11-21 04:02PM	C4 Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results GlobeNewswire
04:01PM	C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of Multiple Myeloma GlobeNewswire
Aug-10-21 01:31AM	Is C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Shareholder Ownership Skewed Towards Insiders? Simply Wall St.
Jul-21-21 04:24AM	Is C4 Therapeutics, Inc. (CCCC) A Good Stock To Buy Now? Insider Monkey
Jul-19-21 01:44PM	C4 Therapeutics Stock Enters Leadership Territory Investor's Business Daily
Jun-21-21 04:01PM	C4 Therapeutics Announces Closing of Public Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares GlobeNewswire
08:00AM	C4 Therapeutics Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the 16th Annual International Conference on Malignant Lymphoma GlobeNewswire
Jun-16-21 07:51PM	C4 Therapeutics Announces Pricing of Public Offering GlobeNewswire
Jun-14-21 04:12PM	C4 Therapeutics Launches Proposed Public Offering GlobeNewswire
08:00AM	C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT7455, An Orally Bioavailable MonoDAC for Hematologic Malignancies GlobeNewswire
Jun-07-21 07:00AM	C4 Therapeutics Presents Pre-clinical Data on CFT8919, A Selective Degrader of EGFR L858R, at Keystone Symposium on Targeted Protein Degradation GlobeNewswire +6.17%
May-26-21 07:00AM	C4 Therapeutics to Advance CFT8919, A Selective Degrader of EGFR L858R, Into IND-enabling Studies GlobeNewswire +7.61%
May-20-21 04:01PM	C4 Therapeutics Appoints Lauren White as Chief Financial Officer GlobeNewswire
May-13-21 04:01PM	C4 Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results GlobeNewswire
May-12-21 07:00AM	C4 Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
May-02-21 03:53AM	Did C4 Therapeutics, Inc. (NASDAQ:CCCC) Insiders Buy Up More Shares? Simply Wall St.
Apr-10-21 03:05PM	C4 Therapeutics Presents Preclinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the AACR Annual Meeting 2021 GlobeNewswire
Mar-10-21 04:41PM	C4 Therapeutics to Present on the Discovery and Preclinical Development of CFT7455, a MonoDAC Degrader Targeting IKZF1/3, at the American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Mar-02-21 11:50PM	How Much Of C4 Therapeutics, Inc. (NASDAQ:CCCC) Do Insiders Own? Simply Wall St.
Feb-24-21 07:00AM	C4 Therapeutics to Participate in Upcoming March Investor Conferences GlobeNewswire
Feb-11-21 07:00AM	C4 Therapeutics to Participate in BMO BioPharma Spotlight Series GlobeNewswire
Jan-19-21 07:00AM	C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT7455, an Orally Bioavailable MonoDAC for Hematologic Malignancies GlobeNewswire
Jan-07-21 07:00AM	C4 Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-06-21 07:00AM	C4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four Clinical-Stage Programs by Year-End 2022 GlobeNewswire
Dec-17-20 07:00AM	C4 Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes GlobeNewswire
Nov-25-20 07:00AM	C4 Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx GlobeNewswire
Nov-13-20 07:00AM	C4 Therapeutics to Present at the Jefferies Virtual London Healthcare Conference GlobeNewswire
Nov-12-20 04:05PM	C4 Therapeutics Reports Business Highlights and Third Quarter 2020 Financial Results GlobeNewswire
Oct-23-20 05:54PM	Shattuck Labs, C4 Therapeutics See Activist Actions Barrons.com
Oct-14-20 07:30AM	C4 Therapeutics to Present at the 3rd Annual Targeted Protein Degradation Summit GlobeNewswire
Oct-06-20 04:05PM	C4 Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares GlobeNewswire
Oct-02-20 05:53PM	Academy Sports Stock Falls Below $13 IPO Price in First Day of Trading Barrons.com
11:23AM	3 Biotech Companies Are Making Their Market Debuts Barrons.com
Oct-01-20 09:58PM	C4 Therapeutics Announces Pricing of an Upsized Initial Public Offering GlobeNewswire

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Anderson Kenneth Carl	Director	Oct 03	Option Exercise	3.90	712	2,779	91,698	Oct 04 06:05 PM
Anderson Kenneth Carl	Director	Jul 15	Option Exercise	3.90	1,424	5,556	90,986	Jul 18 05:18 PM
Fisher Stewart	Chief Scientific Officer	Apr 12	Option Exercise	4.88	28,084	137,120	71,390	Apr 12 08:41 PM
Hirsch Andrew	President & CEO	Apr 12	Buy	8.40	10,000	84,000	10,000	Apr 12 04:05 PM
Anderson Kenneth Carl	Director	Jan 26	Option Exercise	3.90	2,137	8,338	87,975	Jan 26 05:26 PM
Crystal Adam	Chief Medical Officer	Jan 04	Option Exercise	6.49	15,000	97,350	30,000	Jan 05 04:30 PM
Crystal Adam	Chief Medical Officer	Jan 04	Sale	31.66	15,000	474,968	15,000	Jan 05 04:30 PM
Crystal Adam	Chief Medical Officer	Dec 22	Option Exercise	6.49	5,000	32,450	15,000	Dec 23 04:10 PM
Salter Malcolm	Director	Dec 17	Sale	30.25	755	22,839	10,952	Dec 17 04:28 PM
Fisher Stewart	Chief Scientific Officer	Dec 08	Option Exercise	3.55	20,562	73,000	43,306	Dec 10 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience